News Column

New Chemotherapy Study Findings Have Been Reported by Investigators at Thomas Jefferson University

June 18, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies have been published. According to news reporting originating in Philadelphia, Pennsylvania, by NewsRx journalists, research stated, "It is predicted that the incidence of mesothelioma will increase and thus it is important to find new ways to treat this chemoresistant tumor. Glutathione-S-Transferase pi (GST pi) is found at significant levels in mesotheliomas and thus attenuating its intracellular levels may provide a means of sensitizing mesothe- lioma cells to chemotherapy."

The news reporters obtained a quote from the research from Thomas Jefferson University, "GST pi knockdowns were therefore prepared with shRNA (less off-target effects) employing two cell lines (211H, H2452) that were typed by immunohistochemistry to be of mesothelial origin. The knockdowns exhibited a decrease in both total GST enzyme activity and GST pi protein levels as well as an increase in both glutathione levels and sensitivity to cis and oxaliplatin. Cisplatin treatment of the knockdowns increased ROS levels significantly (as compared to the parental cells) and produced activation of the JNK/p38 pathways and activating transcription factor (ATF2). The degree of activation and increase in ROS appeared to correlate with the cell line's sensitivity to cisplatin. Treatment with N-Acetyl Cysteine decreased ROS production and JNK/p38 phosphorylation but had minimal affect on ATF2 suggesting a direct interaction of GTP pi with this transcription factor. Oxaliplatin treatment produced only minimal changes in ROS levels and activation of the JNK/p38 pathway."

According to the news reporters, the research concluded: "Recently, new methods of siRNA delivery (nanoparticles) have been shown to be effective in decreasing the levels of target proteins in humans including candidate genes involved in drug resistance thus this approach may have promise in sensitizing cisplatin-resistant tumors to chemotherapy."

For more information on this research see: Sensitization of mesothelioma cells to platinum-based chemotherapy by GST pi knockdown. Biochemical and Biophysical Research Communications, 2014;447(1):77-82. Biochemical and Biophysical Research Communications can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Biochemical and Biophysical Research Communications - www.elsevier.com/wps/product/cws_home/622790)

Our news correspondents report that additional information may be obtained by contacting J.L. Chen, Thomas Jefferson University, Jefferson Med College, Dept. of Pathol Anat & Cell Biol, Philadelphia, PA 19107, United States. Additional authors for this research include C. Solomides and H. Simpkins (see also Drugs and Therapies).

Keywords for this news article include: Antineoplastics, Pharmaceuticals, Genetics, Cisplatin, Philadelphia, Pennsylvania, Chemotherapy, United States, Mesotheliomas, Alkylating Agents, Chlorine Compounds, Nitrogen Compounds, Platinum Compounds, Drugs and Therapies, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters